Frederick G Freitag

Summary

Publications

  1. doi request reprint Why do migraines often decrease as we age?
    Frederick G Freitag
    Department of Neurology, Medical College of Wisconsin, Milwaukee, 53226, USA
    Curr Pain Headache Rep 17:366. 2013
  2. doi request reprint Managing and treating tension-type headache
    Frederick Freitag
    Department of Neurosciences, Baylor University Medical Center, Dallas, TX 75231, USA
    Med Clin North Am 97:281-92. 2013
  3. doi request reprint Sumatriptan needle-free subcutaneous (Sumavel(®) DosePro™) approved for the acute treatment of migraine, with or without aura, and cluster headaches
    Frederick G Freitag
    Comprehensive Headache Center, Baylor University Medical Center, 9101 North Central Expressway 400, Dallas, TX 75231, USA
    Expert Rev Neurother 11:481-90. 2011

Detail Information

Publications3

  1. doi request reprint Why do migraines often decrease as we age?
    Frederick G Freitag
    Department of Neurology, Medical College of Wisconsin, Milwaukee, 53226, USA
    Curr Pain Headache Rep 17:366. 2013
    ..Systems rarely thought of in terms of neurologic disease such as the inflammatory system may have significant contributions to modulating this process and accounting for the clinical presentation of migraine...
  2. doi request reprint Managing and treating tension-type headache
    Frederick Freitag
    Department of Neurosciences, Baylor University Medical Center, Dallas, TX 75231, USA
    Med Clin North Am 97:281-92. 2013
    ....
  3. doi request reprint Sumatriptan needle-free subcutaneous (Sumavel(®) DosePro™) approved for the acute treatment of migraine, with or without aura, and cluster headaches
    Frederick G Freitag
    Comprehensive Headache Center, Baylor University Medical Center, 9101 North Central Expressway 400, Dallas, TX 75231, USA
    Expert Rev Neurother 11:481-90. 2011
    ..A new method of delivery for this agent, Sumavel(®) DosePro™, eliminates the needle and disposal issues coupled with an improved ease of use of drug delivery and acceptable tolerability for patients in clinical trials...